KR102264514B1 - Lytic bacteriophage specific for klebsiella genus resistant to antibiotics - Google Patents
Lytic bacteriophage specific for klebsiella genus resistant to antibiotics Download PDFInfo
- Publication number
- KR102264514B1 KR102264514B1 KR1020170077539A KR20170077539A KR102264514B1 KR 102264514 B1 KR102264514 B1 KR 102264514B1 KR 1020170077539 A KR1020170077539 A KR 1020170077539A KR 20170077539 A KR20170077539 A KR 20170077539A KR 102264514 B1 KR102264514 B1 KR 102264514B1
- Authority
- KR
- South Korea
- Prior art keywords
- bacteriophage
- ymc15
- atc
- present
- klebsiella
- Prior art date
Links
- 241001515965 unidentified phage Species 0.000 title claims abstract description 100
- 239000003242 anti bacterial agent Substances 0.000 title claims abstract description 28
- 241000588748 Klebsiella Species 0.000 title abstract description 48
- 229940088710 antibiotic agent Drugs 0.000 title abstract description 16
- 230000002101 lytic effect Effects 0.000 title description 18
- 230000003115 biocidal effect Effects 0.000 claims abstract description 49
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 31
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000000645 desinfectant Substances 0.000 claims description 8
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 claims description 5
- 241000702202 Siphoviridae Species 0.000 claims description 5
- 229960000723 ampicillin Drugs 0.000 claims description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 5
- 229960002100 cefepime Drugs 0.000 claims description 5
- 229960002770 ertapenem Drugs 0.000 claims description 5
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 claims description 4
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960003644 aztreonam Drugs 0.000 claims description 4
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 4
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 4
- 229960001139 cefazolin Drugs 0.000 claims description 4
- 229960004261 cefotaxime Drugs 0.000 claims description 4
- 229960002260 meropenem Drugs 0.000 claims description 4
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 4
- 229940104641 piperacillin / tazobactam Drugs 0.000 claims description 4
- 229940043312 ampicillin / sulbactam Drugs 0.000 claims description 3
- 229960002682 cefoxitin Drugs 0.000 claims description 3
- 229960000484 ceftazidime Drugs 0.000 claims description 3
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims description 3
- NWOYIVRVSJDTLK-YSDBFZIDSA-L disodium;(2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylate Chemical compound [Na+].[Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 NWOYIVRVSJDTLK-YSDBFZIDSA-L 0.000 claims description 3
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical compound O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 claims description 3
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims 2
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 claims 1
- 230000022534 cell killing Effects 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 33
- 201000010099 disease Diseases 0.000 abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 230000002147 killing effect Effects 0.000 abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 14
- 235000013305 food Nutrition 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 206010035664 Pneumonia Diseases 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- -1 Levoflocacin Chemical compound 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 241000989318 Escherichia phage Utah Species 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241001641016 Salmonella phage 35 Species 0.000 description 4
- 241001541326 Salmonella virus Chi Species 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010014561 Emphysema Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101710126949 Lysin Proteins 0.000 description 3
- 241001640996 Salmonella phage 37 Species 0.000 description 3
- 241000456882 Salmonella virus FSLSP030 Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229940096118 ella Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 3
- 101100351191 Autographa californica nuclear polyhedrosis virus PCNA gene Proteins 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241001370343 Enterobacter phage Enc34 Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 description 2
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 101150050790 ORF49 gene Proteins 0.000 description 2
- 101000783504 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 15.4 kDa protein Proteins 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 101710118890 Photosystem II reaction center protein Ycf12 Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000588746 Raoultella planticola Species 0.000 description 2
- 241000588756 Raoultella terrigena Species 0.000 description 2
- 241001518594 Salmonella phage BP12C Species 0.000 description 2
- 241000456879 Salmonella phage FSL SP-019 Species 0.000 description 2
- 241000456876 Salmonella phage FSL SP-124 Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 101710166729 Tail fiber protein Proteins 0.000 description 2
- 101710198378 Uncharacterized 10.8 kDa protein in cox-rep intergenic region Proteins 0.000 description 2
- 101710173665 Uncharacterized 5.8 kDa protein Proteins 0.000 description 2
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 2
- 101710134973 Uncharacterized 9.7 kDa protein in cox-rep intergenic region Proteins 0.000 description 2
- 101710172361 Uncharacterized protein ycf17 Proteins 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960003376 levofloxacin Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000010865 sewage Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960003865 tazobactam Drugs 0.000 description 2
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101710115267 ATP synthase protein MI25 Proteins 0.000 description 1
- 101710183434 ATPase Proteins 0.000 description 1
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 description 1
- 101000748061 Acholeplasma phage L2 Uncharacterized 16.1 kDa protein Proteins 0.000 description 1
- 101000818123 Acholeplasma phage L2 Uncharacterized 17.2 kDa protein Proteins 0.000 description 1
- 101000818089 Acholeplasma phage L2 Uncharacterized 25.6 kDa protein Proteins 0.000 description 1
- 101000827329 Acholeplasma phage L2 Uncharacterized 26.1 kDa protein Proteins 0.000 description 1
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 1
- 101000818108 Acholeplasma phage L2 Uncharacterized 81.3 kDa protein Proteins 0.000 description 1
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 1
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 1
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 1
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 1
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 1
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 1
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 1
- 101000748781 Anthoceros angustus Uncharacterized 3.0 kDa protein in psbT-psbN intergenic region Proteins 0.000 description 1
- 101000812031 Anthoceros angustus Uncharacterized 5.9 kDa protein in rps16-psbA intergenic region Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 101100214868 Autographa californica nuclear polyhedrosis virus AC54 gene Proteins 0.000 description 1
- 101100074342 Autographa californica nuclear polyhedrosis virus LEF-11 gene Proteins 0.000 description 1
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 description 1
- 101000770875 Autographa californica nuclear polyhedrosis virus Uncharacterized 14.2 kDa protein in PK1-LEF1 intergenic region Proteins 0.000 description 1
- 101000781183 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.4 kDa protein in IAP1-SOD intergenic region Proteins 0.000 description 1
- 101000847476 Autographa californica nuclear polyhedrosis virus Uncharacterized 54.7 kDa protein in IAP1-SOD intergenic region Proteins 0.000 description 1
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 1
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 description 1
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 1
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 1
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 1
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 description 1
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 1
- 101000736075 Bacillus subtilis (strain 168) Uncharacterized protein YcbP Proteins 0.000 description 1
- 101000736076 Bacillus subtilis (strain 168) Uncharacterized protein YcbR Proteins 0.000 description 1
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 1
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 description 1
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 1
- 101000786247 Bacillus subtilis (strain 168) Uncharacterized protein YqaT Proteins 0.000 description 1
- 101000916131 Bacillus subtilis (strain 168) Uncharacterized protein YqxA Proteins 0.000 description 1
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 description 1
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 1
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 1
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 1
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 description 1
- 101000774107 Borrelia burgdorferi (strain ATCC 35210 / B31 / CIP 102532 / DSM 4680) Uncharacterized protein BB_0266 Proteins 0.000 description 1
- 101000631235 Borrelia burgdorferi (strain ATCC 35210 / B31 / CIP 102532 / DSM 4680) Uncharacterized protein BB_0268 Proteins 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 241000997471 Burkholderia phage BcepNazgul Species 0.000 description 1
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 description 1
- 101000736909 Campylobacter jejuni Probable nucleotidyltransferase Proteins 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 101000748745 Chlamydomonas reinhardtii Uncharacterized 6.2 kDa protein in psaC-petL intergenic region Proteins 0.000 description 1
- 101000626907 Chlamydomonas reinhardtii Uncharacterized 7.3 kDa protein in petA 5'region Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 description 1
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 1
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 description 1
- 101000947615 Clostridium perfringens Uncharacterized 38.4 kDa protein Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100039200 Constitutive coactivator of PPAR-gamma-like protein 2 Human genes 0.000 description 1
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 1
- 101001017206 Coxiella burnetii (strain RSA 493 / Nine Mile phase I) Histone-like protein Hq1 Proteins 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 101000792449 Cyanophora paradoxa Uncharacterized 3.4 kDa protein in atpE-petA intergenic region Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101150026402 DBP gene Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 101710159129 DNA adenine methylase Proteins 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102100024101 DnaJ homolog subfamily C member 28 Human genes 0.000 description 1
- 101000747774 Enterobacteria phage 82 Uncharacterized protein in rusA 3'region Proteins 0.000 description 1
- 101000953091 Enterobacteria phage P4 Uncharacterized protein ORF88 Proteins 0.000 description 1
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 101000964391 Enterococcus faecalis UPF0145 protein Proteins 0.000 description 1
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 1
- 241000639569 Erwinia phage PEp14 Species 0.000 description 1
- 101100173936 Escherichia coli (strain K12) flmA gene Proteins 0.000 description 1
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 1
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 description 1
- 241000068902 Escherichia phage K1-ind(3) Species 0.000 description 1
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 description 1
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 1
- 241001382533 Escherichia phage SerU-LTIIb Species 0.000 description 1
- 101000748786 Euglena longa Uncharacterized 7.2 kDa protein in rps2-rps9 intergenic region Proteins 0.000 description 1
- 101000792446 Euglena longa Uncharacterized 8.7 kDa protein in rpl22-rpl23 intergenic region Proteins 0.000 description 1
- 101000748747 Euglena longa Uncharacterized 9.2 kDa protein in rpl23-rpl2 intergenic region Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 1
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 1
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101000626903 Guillardia theta Uncharacterized 6.1 kDa protein Proteins 0.000 description 1
- 101000792437 Guillardia theta Uncharacterized 7.8 kDa protein Proteins 0.000 description 1
- 101000626971 Guillardia theta Uncharacterized 8.1 kDa protein Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 1
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 1
- 101000912350 Haemophilus phage HP1 (strain HP1c1) DNA N-6-adenine-methyltransferase Proteins 0.000 description 1
- 101000933958 Haemophilus phage HP1 (strain HP1c1) Major capsid protein Proteins 0.000 description 1
- 101000743338 Haemophilus phage HP1 (strain HP1c1) Probable head completion/stabilization protein Proteins 0.000 description 1
- 101001066788 Haemophilus phage HP1 (strain HP1c1) Probable portal protein Proteins 0.000 description 1
- 101001052021 Haemophilus phage HP1 (strain HP1c1) Probable tail fiber protein Proteins 0.000 description 1
- 101000854890 Haemophilus phage HP1 (strain HP1c1) Probable terminase, ATPase subunit Proteins 0.000 description 1
- 101000743335 Haemophilus phage HP1 (strain HP1c1) Probable terminase, endonuclease subunit Proteins 0.000 description 1
- 101000748063 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 11.1 kDa protein in rep-hol intergenic region Proteins 0.000 description 1
- 101000758973 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 11.3 kDa protein in lys 3'region Proteins 0.000 description 1
- 101000758963 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 12.7 kDa protein in lys 3'region Proteins 0.000 description 1
- 101000976893 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 14.1 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 101000818057 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 14.9 kDa protein in rep-hol intergenic region Proteins 0.000 description 1
- 101000818121 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 18.2 kDa protein in rep-hol intergenic region Proteins 0.000 description 1
- 101000786896 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in rep-hol intergenic region Proteins 0.000 description 1
- 101000708358 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 23.3 kDa protein in lys 3'region Proteins 0.000 description 1
- 101000786921 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 26.0 kDa protein in rep-hol intergenic region Proteins 0.000 description 1
- 101000948764 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 58.7 kDa protein in lys 3'region Proteins 0.000 description 1
- 101000768945 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 7.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 1
- 101000748060 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.3 kDa protein in rep-hol intergenic region Proteins 0.000 description 1
- 101000977016 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 1
- 101710115484 Head-tail joining protein Proteins 0.000 description 1
- 101000626607 Herpetosiphon aurantiacus Putative type II restriction enzyme HgiDII Proteins 0.000 description 1
- 101000623276 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiBIM 5'region Proteins 0.000 description 1
- 101000623175 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiCIIM 5'region Proteins 0.000 description 1
- 101000626850 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiEIM 5'region Proteins 0.000 description 1
- 101000748192 Herpetosiphon aurantiacus Uncharacterized 15.4 kDa protein in HgiDIIM 5'region Proteins 0.000 description 1
- 101700012268 Holin Proteins 0.000 description 1
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 1
- 101001053999 Homo sapiens DnaJ homolog subfamily C member 28 Proteins 0.000 description 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 1
- 101001028836 Homo sapiens M-phase-specific PLK1-interacting protein Proteins 0.000 description 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
- 101000652805 Homo sapiens Protein shisa-8 Proteins 0.000 description 1
- 101000820589 Homo sapiens Succinate-hydroxymethylglutarate CoA-transferase Proteins 0.000 description 1
- 101000667300 Homo sapiens WD repeat-containing protein 19 Proteins 0.000 description 1
- 101100064352 Human herpesvirus 8 type P (isolate GK18) DUT gene Proteins 0.000 description 1
- 101100100297 Human herpesvirus 8 type P (isolate GK18) TRM3 gene Proteins 0.000 description 1
- 101100283436 Human herpesvirus 8 type P (isolate GK18) gM gene Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102100024407 Jouberin Human genes 0.000 description 1
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 1
- 238000002768 Kirby-Bauer method Methods 0.000 description 1
- 241000588749 Klebsiella oxytoca Species 0.000 description 1
- 101000578717 Klebsiella pneumoniae Mannose-1-phosphate guanylyltransferase Proteins 0.000 description 1
- 101000957786 Klebsiella pneumoniae Phosphomannomutase Proteins 0.000 description 1
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 description 1
- 101001015100 Klebsiella pneumoniae UDP-glucose:undecaprenyl-phosphate glucose-1-phosphate transferase Proteins 0.000 description 1
- 101000790838 Klebsiella pneumoniae UPF0053 protein in cps region Proteins 0.000 description 1
- 101000790837 Klebsiella pneumoniae Uncharacterized 18.9 kDa protein in cps region Proteins 0.000 description 1
- 101000790844 Klebsiella pneumoniae Uncharacterized 24.8 kDa protein in cps region Proteins 0.000 description 1
- 101000790840 Klebsiella pneumoniae Uncharacterized 49.5 kDa protein in cps region Proteins 0.000 description 1
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 1
- 101000790842 Klebsiella pneumoniae Uncharacterized 65.4 kDa protein in cps region Proteins 0.000 description 1
- 101000768313 Klebsiella pneumoniae Uncharacterized membrane protein in cps region Proteins 0.000 description 1
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 1
- 101000904276 Lactococcus phage P008 Gene product 38 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 1
- 101000756286 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 10.9 kDa protein in LEF8-FP intergenic region Proteins 0.000 description 1
- 101000759330 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized protein in LEF8-FP intergenic region Proteins 0.000 description 1
- 102100037185 M-phase-specific PLK1-interacting protein Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101000626970 Marchantia polymorpha Uncharacterized 3.3 kDa protein in psbT-psbN intergenic region Proteins 0.000 description 1
- 101000626905 Marchantia polymorpha Uncharacterized 3.8 kDa protein in ycf12-psaM intergenic region Proteins 0.000 description 1
- 101000748779 Marchantia polymorpha Uncharacterized 6.4 kDa protein in atpA-psbA intergenic region Proteins 0.000 description 1
- 101000788536 Marchantia polymorpha Uncharacterized mitochondrial protein ymf22 Proteins 0.000 description 1
- 101000788487 Marchantia polymorpha Uncharacterized mitochondrial protein ymf25 Proteins 0.000 description 1
- 101000788489 Marchantia polymorpha Uncharacterized mitochondrial protein ymf26 Proteins 0.000 description 1
- 101000788491 Marchantia polymorpha Uncharacterized mitochondrial protein ymf27 Proteins 0.000 description 1
- 101000747938 Marchantia polymorpha Uncharacterized mitochondrial protein ymf31 Proteins 0.000 description 1
- 101000747949 Marchantia polymorpha Uncharacterized mitochondrial protein ymf32 Proteins 0.000 description 1
- 101000747945 Marchantia polymorpha Uncharacterized mitochondrial protein ymf34 Proteins 0.000 description 1
- 101710159527 Maturation protein A Proteins 0.000 description 1
- 101710091157 Maturation protein A2 Proteins 0.000 description 1
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 1
- 101000804418 Methanothermobacter thermautotrophicus (strain ATCC 29096 / DSM 1053 / JCM 10044 / NBRC 100330 / Delta H) Uncharacterized protein MTH_1463 Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 1
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 1
- 102100023897 NADPH-cytochrome P450 reductase Human genes 0.000 description 1
- 101000774651 Naja atra Zinc metalloproteinase-disintegrin-like kaouthiagin-like Proteins 0.000 description 1
- 101100521838 Nicotiana tabacum pbf1 gene Proteins 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 101150101223 ORF29 gene Proteins 0.000 description 1
- 101150020791 ORF37 gene Proteins 0.000 description 1
- 101150016564 ORF39 gene Proteins 0.000 description 1
- 101150075249 ORF40 gene Proteins 0.000 description 1
- 101150006817 ORF43 gene Proteins 0.000 description 1
- 101150104094 ORF52 gene Proteins 0.000 description 1
- 101150098690 ORF54 gene Proteins 0.000 description 1
- 101710087110 ORF6 protein Proteins 0.000 description 1
- 101150092861 ORF71 gene Proteins 0.000 description 1
- 101100389785 Orgyia pseudotsugata multicapsid polyhedrosis virus ETM gene Proteins 0.000 description 1
- 101100069690 Orgyia pseudotsugata multicapsid polyhedrosis virus GTA gene Proteins 0.000 description 1
- 101100306237 Orgyia pseudotsugata multicapsid polyhedrosis virus LEF-8 gene Proteins 0.000 description 1
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 1
- 101100096140 Orgyia pseudotsugata multicapsid polyhedrosis virus SOD gene Proteins 0.000 description 1
- 101000666843 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 24.0 kDa protein Proteins 0.000 description 1
- 101000770899 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 24.3 kDa protein Proteins 0.000 description 1
- 101000781204 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 36.6 kDa protein Proteins 0.000 description 1
- 101000770870 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 37.2 kDa protein Proteins 0.000 description 1
- 101000805098 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 73.1 kDa protein Proteins 0.000 description 1
- 101000768120 Oryza nivara Uncharacterized protein ycf76 Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101100378791 Paenarthrobacter nicotinovorans aldh gene Proteins 0.000 description 1
- 101100156835 Paenarthrobacter nicotinovorans xdh gene Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 1
- 101100481711 Pneumococcus phage Dp-1 TMP gene Proteins 0.000 description 1
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 1
- 101000764206 Porphyra purpurea Uncharacterized protein in rpl9-rpl11 intergenic region Proteins 0.000 description 1
- 108050005751 Portal proteins Proteins 0.000 description 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710197985 Probable protein Rev Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101710146616 Prohead protease Proteins 0.000 description 1
- 102100040307 Protein FAM3B Human genes 0.000 description 1
- 241000417109 Providencia phage Redjac Species 0.000 description 1
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 1
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 1
- 241000954595 Pseudomonas phage MP1412 Species 0.000 description 1
- 241000476554 Pseudomonas phage PaMx11 Species 0.000 description 1
- 241001610516 Pseudomonas phage vB_PaeS_PAO1_Ab18 Species 0.000 description 1
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 1
- 101000708297 Pseudomonas stutzeri Uncharacterized 8.5 kDa protein in nirQ 3'region Proteins 0.000 description 1
- 101710193192 Putative transcriptional regulator Proteins 0.000 description 1
- 101710089184 Putative uncharacterized protein ycf15 Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 1
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 description 1
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 description 1
- 101000748499 Rhodobacter capsulatus Uncharacterized 104.1 kDa protein in hypE 3'region Proteins 0.000 description 1
- 101000748505 Rhodobacter capsulatus Uncharacterized 16.1 kDa protein in hypE 3'region Proteins 0.000 description 1
- 101000827754 Rhodobacter capsulatus Uncharacterized 5.8 kDa protein in puhA 5'region Proteins 0.000 description 1
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 description 1
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 1
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 1
- 101000768117 Saccharum officinarum Uncharacterized protein ycf70 Proteins 0.000 description 1
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 1
- 101000814063 Salmonella phage P22 Uncharacterized 6.6 kDa protein in eae-abc2 intergenic region Proteins 0.000 description 1
- 101000953980 Salmonella phage P22 Uncharacterized 7.7 kDa protein in gp5-gp4 intergenic region Proteins 0.000 description 1
- 101000953981 Salmonella phage P22 Uncharacterized 7.8 kDa protein in ral-gp17 intergenic region Proteins 0.000 description 1
- 101000736813 Salmonella phage P22 Uncharacterized 8.6 kDa protein in ral-gp17 intergenic region Proteins 0.000 description 1
- 101000953093 Salmonella phage P22 Uncharacterized 9.0 kDa protein in gp15-gp3 intergenic region Proteins 0.000 description 1
- 101000788145 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Uncharacterized protein YpfL Proteins 0.000 description 1
- 241000456873 Salmonella virus FSLSP088 Species 0.000 description 1
- 241001010516 Salmonella virus SPN19 Species 0.000 description 1
- 241000092432 Serratia marcescens SM39 Species 0.000 description 1
- 101000992423 Severe acute respiratory syndrome coronavirus 2 Putative ORF9c protein Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000543700 Staphylococcus virus Twort Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 1
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 1
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 description 1
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 1
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 description 1
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 1
- 101000708364 Streptomyces griseus Uncharacterized 31.2 kDa protein in rplA-rplJ intergenic region Proteins 0.000 description 1
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 1
- 101000953979 Streptomyces lividans Uncharacterized 6.6 kDa protein Proteins 0.000 description 1
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 description 1
- 102100021652 Succinate-hydroxymethylglutarate CoA-transferase Human genes 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 101710128479 Tail assembly protein G Proteins 0.000 description 1
- 101710199973 Tail tube protein Proteins 0.000 description 1
- 101710204224 Tape measure protein Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 1
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 description 1
- 101000764204 Trieres chinensis Uncharacterized 3.3 kDa protein in rpl11-trnW intergenic region Proteins 0.000 description 1
- 101000792450 Trieres chinensis Uncharacterized 4.7 kDa protein in ycf33-trnY intergenic region Proteins 0.000 description 1
- 101000748762 Trieres chinensis Uncharacterized 5.4 kDa protein in trnK-psbC intergenic region Proteins 0.000 description 1
- 101000626900 Trieres chinensis Uncharacterized 5.5 kDa protein in ccsA-rps6 intergenic region Proteins 0.000 description 1
- 101710091588 Tripartite terminase subunit 3 Proteins 0.000 description 1
- 101000768114 Triticum aestivum Uncharacterized protein ycf70 Proteins 0.000 description 1
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 1
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 description 1
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 1
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102100039744 WD repeat-containing protein 19 Human genes 0.000 description 1
- 101000736254 Zea mays Uncharacterized protein ycf70 Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003006 anti-agglomeration agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 108010068385 carbapenemase Proteins 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 101150055782 gH gene Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 101150012611 lys gene Proteins 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 101150055367 orf47 gene Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000002435 rhinoplasty Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/127—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Abstract
본 발명은 항생제에 대한 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균시키는 박테리오파지에 관한 것으로, YMC15/11/N137_KPN_BP 박테리오파지 (기탁번호: [KCTC18573P])를 제공한다.
본 발명에서 제공하는 항생제 내성 클렙시엘라속 균에 대하여 특이적 사멸능을 가지므로, 항생제 내성 클렙시엘라속 균에 의해 유발되는 질환의 예방 및 치료 목적으로 활용할 수 있다. The present invention relates to a bacteriophage that lyses bacteria of the genus Klebsiella with resistance to antibiotics, and provides a YMC15/11/N137_KPN_BP bacteriophage (Accession No.: [KCTC18573P]).
Since it has a specific killing ability against antibiotic-resistant Klebsiella bacteria provided in the present invention, it can be used for the purpose of preventing and treating diseases caused by antibiotic-resistant Klebsiella bacteria.
Description
본 발명은 항생제에 대한 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균시키는 박테리오파지에 관한 것이다.The present invention relates to a bacteriophage that lyses bacteria of the genus Klebsiella having resistance to antibiotics.
클렙시엘라(Klebsiella)속 균에 해당하는 클렙시엘라 뉴모니아(Klebsiella pneumoniae)는 그람 음성의 피막을 가진 혐기성 세균으로 입, 피부, 장 등의 정상세균총에서 발견된다. 병원 밖 클렙시엘라 세균에 의해 유발되는 가장 흔한 감염질환은 폐렴이 있으며, 전형적으로 기관지폐렴 및 기관지염의 형태로 나타난다. 클렙시엘라 뉴모니아는 감염 및 출혈을 통해 인간 폐를 파괴할 수 있고, 때로는 점액성 객담을 생성하기도 한다. 상기 세균은 전형적으로 구강 인두에 대량으로 서식하는 미생물 흡입에 의해 기도로 들어가 감염을 유발하는 것으로 알려져 있다.Klebsiella ( Klebsiella ) Corresponding to the genus Klebsiella pneumoniae ( Klebsiella pneumoniae ) is an anaerobic bacterium with a Gram-negative coating and is found in normal flora of the mouth, skin, and intestines. The most common infectious disease caused by Klebsiella bacteria outside the hospital is pneumonia, which typically appears in the form of bronchopneumonia and bronchitis. Klebsiella pneumoniae can destroy human lungs through infection and bleeding, sometimes producing mucous sputum. These bacteria are known to enter the airways and cause infections by inhalation of microorganisms that typically inhabit the oropharynx in large numbers.
상기 클렙시엘라속 균의 감염은 대부분 면역력이 약한 사람에게서 두드러지게 나타나며, 항균 치료를 수행하더라도 약 50%의 높은 사망률을 나타내고 있다. 특히, 클렙시엘라 뉴모니아는 구강 등의 흡입 이외에도 비뇨기관, 쓸개관 및 수술에 의한 상처 부위에서도 감염을 유발할 수 있다. 최근, 클렙시엘라 뉴모니아가 병원 내 감염에 있어서 매우 중요한 병원균으로 인식되고 있다.Infection of the genus Klebsiella is most noticeable in people with weak immunity, and even if antibacterial treatment is performed, it has a high mortality rate of about 50%. In particular, Klebsiella pneumoniae can cause infection in the urinary tract, bile duct, and surgical wounds in addition to oral inhalation. Recently, Klebsiella pneumoniae has been recognized as a very important pathogen in nosocomial infection.
항생제 오남용 및 이로 인한 내성균 출현 등으로 대표되는 기존 합성 항생제의 문제점이 세계적으로 크게 이슈화되어 있는 상황에서 이에 대한 해결책을 제시해 줄 수 있는 대상으로 주목을 받고 있는 것이 바로 박테리오파지(Bacteriophage) 및 박테리오파지 유래의 리신(Lysin) 단백질이다. 박테리오파지 및 리신 단백질은 기존 항생 물질과는 완전히 다른 계열이라 할 수 있으며 이에 따라 전혀 다른 항균(antibacterial) 작용 기작(mode of action)을 갖고 있다. 따라서 기존 항생제의 사용에서 나타나던 여러 부작용(side effect)이나 문제점을 개선할 수 있을 것으로 기대를 모으고 있다.Bacteriophage and lysin derived from bacteriophage are attracting attention as a target that can suggest a solution in a situation in which the problems of existing synthetic antibiotics, such as the misuse of antibiotics and the emergence of resistant bacteria, are a major issue around the world. (Lysin) protein. Bacteriophage and lysin protein can be said to be a completely different family from existing antibiotics, and thus have a completely different antibacterial mode of action. Therefore, it is expected that various side effects and problems that have been seen in the use of existing antibiotics can be improved.
박테리오파지는 박테리아를 감염시킬 수 있으며 보통 파지(phage)라고 줄여서 부르기도 한다. 박테리오파지는 핵산으로 이루어진 유전물질 중심부를 단백질 외피가 싸고 있는 단순한 구조의 유기체이며, 핵산은 단일 사슬이거나 이중 사슬인 DNA 또는 RNA로 되어있다. 박테리오파지는 생존에 숙주(host)가 반드시 필요하며, 모든 박테리아에는 특정 박테리오파지가 존재한다고 알려져 있다. 박테리오파지는 박테리아의 세포벽(cell wall)의 펩티도글리칸(peptidoglycan) 층(layer)을 공격하여 세포벽을 파괴함으로써 박테리아를 사멸시킬 수 있다. 박테리오파지는 1915년 영국의 세균학자 Twort와 1917년 프랑스의 dHerelle에 의해 독립적으로 규명되었으며 세균을 잡아먹는다는 뜻에서 박테리오파지라고 명명되었다. 박테리오파지의 항박테리아 활성(antibacterial activity) 때문에 발견 직후부터 인체와 동물의 질병 치료에 사용되었다. 그러나 Flemming에 의해 페니실린이 발견된 이후, 계속된 다양한 항생제의 등장 및 보급화로 인하여 서구에서는 관심이 점차 줄어들게 되었다. 그러나 러시아와 독일 등의 동구권 나라들은 박테리오파지 연구를 계속 해왔으며 관련하여 다수의 제품들이 산업화된 바도 있다. 하지만, 2000년대에 이르러 항생제 내성균 문제가 부각되면서 서구에서도 다시 박테리오파지에 대하여 관심을 갖게 되었으며 그 후 약 7~8년이 흐른 최근, 산업화 사례들이 속속 보고되고 있다. 즉, 박테리오파지가 세계적으로 새롭게 재조명되기 시작한 시기는 2000년대 초반으로, 실질적 산업화 노력이 약 7 ~ 8 여년 정도 진행된 신규한 분야로서, 생명공학기술의 발전과 맞물려 최근 매우 활발히 관련 개발이 진행되고 있는 분야라 할 수 있다.Bacteriophages can infect bacteria and are often called phages for short. Bacteriophage is an organism with a simple structure in which a protein coat surrounds the center of a genetic material consisting of nucleic acids, and nucleic acids are composed of single-stranded or double-stranded DNA or RNA. Bacteriophages require a host for survival, and it is known that certain bacteriophages exist in all bacteria. Bacteriophage can kill bacteria by attacking the peptidoglycan layer of the cell wall of the bacteria and destroying the cell wall. Bacteriophage was independently identified by British bacteriologist Twort in 1915 and French dHerelle in 1917, and was named bacteriophage in the sense of eating bacteria. Because of the antibacterial activity of bacteriophages, they have been used for the treatment of diseases in humans and animals immediately after their discovery. However, after penicillin was discovered by Flemming, interest in the West gradually declined due to the continued appearance and dissemination of various antibiotics. However, Eastern European countries such as Russia and Germany have continued to study bacteriophages, and many products have been industrialized in this regard. However, as the problem of antibiotic-resistant bacteria emerged in the 2000s, the West also became interested in bacteriophages again, and industrialization cases have been reported one after another after about 7 to 8 years have passed. That is, the time when bacteriophage began to be re-examined globally was in the early 2000s, a new field in which actual industrialization efforts were carried out for about 7 to 8 years. can be said
박테리오파지의 가장 큰 특징으로는, 감염성 박테리아 속에 침투한 다음 박테리아의 세포벽을 파괴하여 박테리아의 사멸을 유도한다는 것이며, 이러한 박테리오파지에 의한 세포 사멸의 기작은 세균의 세포벽 합성을 방해하는 방식의 기존 합성 항생제의 기작과는 완전히 다르다. 따라서 기존 합성 항생제에 대한 감수성에 관계없이 자신의 항균 활성을 발휘할 수 있다. 이로 인하여 특히 기존 항생제에 대하여 이미 내성을 획득한 내성균에 대해서도 항균 효과가 있다. 또한, 박테리아에 대해서는 매우 특이적인 항균 활성을 가지고 있기 때문에 인간을 포함한 동물을 구성하는 세포인 진핵세포(eukaryotic cell)에는 영향을 주지 않는다는 장점을 갖고 있다.The biggest characteristic of bacteriophage is that it penetrates into infectious bacteria and then destroys the cell wall of the bacteria to induce the death of the bacteria, and the mechanism of cell death by these bacteriophages is that of the existing synthetic antibiotics in a way that interferes with the synthesis of the cell wall of the bacteria. It is completely different from the mechanism. Therefore, it can exert its antibacterial activity regardless of sensitivity to existing synthetic antibiotics. Due to this, in particular, it has an antibacterial effect on resistant bacteria that have already acquired resistance to existing antibiotics. In addition, since it has a very specific antibacterial activity against bacteria, it has an advantage that it does not affect eukaryotic cells, which are cells constituting animals including humans.
본 발명의 일 목적은 항생제 내성 클렙시엘라속 균에 대하여 특이적인 감염 및 세포 사멸 능력을 갖는 신규한 박테리오파지를 제공하는 것이다.One object of the present invention is to provide a novel bacteriophage having a specific infection and apoptosis ability for antibiotic-resistant Klebsiella genus bacteria.
본 발명의 다른 목적은 클렙시엘라속 균에 대하여 특이적인 세포 사멸 능력을 갖는 신규한 박테리오파지를 유효성분으로 포함하여, 상기 클렙시엘라속 균에 의해 유발되는 질환의 예방 또는 치료용 약학 조성물 및 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to include, as an active ingredient, a novel bacteriophage having a specific apoptosis ability for the genus Klebsiella bacteria, and a pharmaceutical composition for preventing or treating diseases caused by the genus Klebsiella bacteria and improvement To provide a food composition for use.
본 발명의 또 다른 목적은 본 발명에 따른 상기 박테리오파지를 포함하는 항생제 및 소독제를 제공하는 것이다.Another object of the present invention is to provide an antibiotic and disinfectant comprising the bacteriophage according to the present invention.
그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업계에서 통상의 지식을 가진 자에게 명확하게 이해될 수 있을 것이다.However, the technical task to be achieved by the present invention is not limited to the tasks mentioned above, and other tasks not mentioned will be clearly understood by those of ordinary skill in the art from the following description.
본 발명의 발명자들은 항생제 내성 세균 감염증 치료의 대안 물질로 기존의 화학 용법 제제를 보완할 수 있는 박테리오파지를 검토하던 중 항생제 내성 클렙시엘라(Klebsiella)속 균을 선택적으로 사멸시킬 수 있는 박테리오파지를 분리하고, 분리된 박테리오파지의 형태적 및 유전적 특성을 분석하여 이를 타 박테리오파지와 구별하여 특정 지을 수 있는 유전체(genome)의 유전자 서열을 제공하며, 더 나아가 항생제 내성 클렙시엘라속 균에 특이적 사멸능을 갖는 분리된 박테리오파지를 이용하여 상기 항생제 내성 클렙시엘라속 균에 의해 유발되는 질환의 예방 및 치료 목적으로 이용함으로써 본 발명을 완성하였다.The inventors of the present invention and remove the bacteriophage capable of selectively killing the spp antibiotic resistance keulrep when Ella (Klebsiella) While reviewing a bacteriophage that can complement existing chemical usage agents as an alternative material of the antibiotic-resistant bacterial infection therapy , by analyzing the morphological and genetic characteristics of the isolated bacteriophage, it provides a gene sequence of the genome that can be specified and differentiated from other bacteriophages, and furthermore, has a specific killing ability for antibiotic-resistant Klebsiella bacteria The present invention was completed by using the isolated bacteriophage having a bacteriophage to prevent and treat diseases caused by the antibiotic-resistant Klebsiella genus.
구체적으로, 본 발명자들은 항생제 내성 클렙시엘라속 균을 선택적으로 사멸시키기 위해 예의 노력한 결과, 병원체로부터 카바페넴 내성을 갖는 클렙시엘라 뉴모니아(Klebsiella pneumoniae)를 분리하였고, 상기 카바페넴 내성 클렙시엘라 뉴모니아를 특이적으로 사멸시킬 수 있는 신규한 박테리오파지를 선별하여 이를 'YMC15/11/N137_KPN_BP'로 명명하였다. 이렇게 선별된 박테리오파지 YMC15/11/N137_KPN_BP를 2017년 5월 11일자로 한국생명공학연구원 미생물자원센터 (기탁번호: [KCTC18573P])에 기탁하였다.Specifically, the present inventors made intensive efforts to selectively kill antibiotic-resistant Klebsiella bacteria, and as a result, Klebsiella pneumoniae having carbapenem resistance was isolated from the pathogen, and the carbapenem-resistant Klebsi A novel bacteriophage capable of specifically killing Ela pneumoniae was selected and named 'YMC15/11/N137_KPN_BP'. The thus-selected bacteriophage YMC15/11/N137_KPN_BP was deposited at the Korea Research Institute of Bioscience and Biotechnology Microbial Resource Center (accession number: [KCTC18573P]) on May 11, 2017.
본 발명의 일 구현 예에 따르면 항생제 내성 클렙시엘라(Klebsiella)속 균에 대하여 선택적 사멸능을 갖는 박테리오파지를 제공한다. According to one embodiment of the present invention provides antibiotic resistance keulrep when bacteriophage having selective killing ability against spp Ella (Klebsiella).
본 발명에서 상기 클렙시엘라(Klebsiella)속 균은 장내세균과의 한 속으로, 협막을 지니며 점액을 생산하고, 탄소원으로서 구연산염을 이용하는 균으로, 자연계에 널리 존재하며 사람의 호흡기, 장관 및 비뇨기에서 검출된다. 일반적으로 상기 균은 비병원성이지만 다양한 질병의 2차 감염과 폐렴 등의 질환의 원인이 될 수 있다. The keulrep when Ella (Klebsiella) Species In the present invention, in one genus of Enterobacteriaceae, said Genie the capsular producing mucus, a fungus using a citrate as a carbon source, widely present in the natural world, and respiratory tract of the person, secretary and urinary is detected in In general, the bacteria are non-pathogenic, but may cause secondary infections of various diseases and diseases such as pneumonia.
본 발명에서, 상기 클렙시엘라속 균은 클렙시엘라 뉴모니아(Klebsiella pneumoniae), 클렙시엘라 옥시토카(Klebsiella oxytoca), 클렙시엘라 플란티콜라(Klebsiella planticola) 및 클렙시엘라 테리게나(Klebsiella terrigena)로 구성된 군으로부터 선택되는 어느 1종 이상일 수 있으며, 바람직하게는 클렙시엘라 뉴모니아(Klebsiella pneumoniae)일 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the Klebsiella genus bacteria Klebsiella pneumoniae ( Klebsiella pneumoniae ), Klebsiella oxytoca ( Klebsiella ) oxytoca ), Klebsiella planticola ( Klebsiella planticola ) and Klebsiella terrigena ( Klebsiella terrigena ) It may be any one or more selected from the group consisting of, preferably Klebsiella pneumoniae ( Klebsiella pneumoniae ) However, it is not limited thereto.
또한, 본 발명에서 상기 클렙시엘라 뉴모니아(Klebsiella pneumoniae)는 간균으로도 불리우며, 아종으로 뉴모니아(Pneumoniae), 아자니아(Azaenae) 및 리노스틸레로마티스(Rhinoscleromatis)가 존재하며, 상기 균은 급성폐렴, 취비증, 비경종증을 유발할 수 있다. 또한, 항생물질에 내성이 존재하고, 건조하지 않는 경우 실온에서 수개월 동안 생존할 수 있다. In addition, in the present invention, the Klebsiella pneumoniae ( Klebsiella pneumoniae ) is also called bacillus, and subspecies of pneumoniae ( Pneumoniae ), azania ( Azaenae ) and rhinoscleromatis ) exist, and the bacteria can cause acute pneumonia, emphysema, and rhinoplasty. . It is also resistant to antibiotics and can survive for months at room temperature if not dried.
본 발명에서 상기 "항생제 내성"은 특정 항생제에 내성을 보여 약효가 듣지 않는 것을 의미하며, 본 발명의 목적상 상기 항생제는 카바페넴(Carbapenem)의 구조를 갖는 항생제일 수 있다. 구체적으로, 아미카신(Amicacin), 앰피실린(Ampicillin), 엠피실린/설벡탐(Ampicillin/Sulbactam), 아즈트레오남(Aztreonam), 세즈타지딤(Ceftazidime), 세파졸린(Cefazolin), 에르타페넴(Ertapenem), 세페핌(Cefepime), 세폭시틴(Cefoxitin), 세포탁심(Cefotaxime), 젠타마이신(Gentamicine), 레보플록세신(Levoflocacin), 메로페넴(Meropenem), 피페라실린/타조박탐(Piperacillin/Tazobactam), 코트리목사(Cotrimoxa), 및 티게틸린(Tigecyline)으로 구성된 군으로부터 선택되는 1종 이상일 수 있으나, 이에 제한되는 것은 아니다. 본 발명의 목적상 상기 클렙시엘라 뉴모니아는 항생제 내성을 갖는 것일 수 있고, 상기 항생제 내성은 상기 카바페넴을 분해하여 효과의 발휘를 억제하는 카바페넴아제 효소(carbapenemase)를 생산함으로써 발생될 수 있다.In the present invention, the "antibiotic resistance" means that the drug is not effective because it shows resistance to a specific antibiotic, and for the purpose of the present invention, the antibiotic may be an antibiotic having a carbapenem structure. Specifically, amikacin, ampicillin, ampicillin/sulbactam, aztreonam, ceftazidime, cefazolin, ertapenem (Ertapenem), Cefepime, Cefoxitin, Cefotaxime, Gentamicine, Levoflocacin, Meropenem, Piperacillin/Tazobactam (Piperacillin) /Tazobactam), Cotrimoxa (Cotrimoxa), and may be at least one selected from the group consisting of Tigecyline (Tigecyline), but is not limited thereto. For the purpose of the present invention, the Klebsiella pneumoniae may have antibiotic resistance, and the antibiotic resistance may be generated by producing a carbapenemase enzyme that inhibits the effect of the carbapenem by decomposing it. .
본 발명에서 상기 “박테리오파지”는 세균을 숙주세포로 하는 바이러스 일군의 총칭으로, 숙주에 감염된 후 증식하여 자손 파지를 방출하는 용균성을 갖는 회로 또는 숙주 염색체와 공존한 상태에서 숙주는 생존하고, 파지 DNA는 복제하는 회로를 갖는다. In the present invention, the "bacteriophage" is a generic term for a group of viruses using bacteria as a host cell, and the host survives in a coexistence with a lytic circuit or host chromosome that proliferates after infection with a host to release progeny phage, and the phage DNA has circuits that replicate.
삭제delete
또한, 본 발명에서 상기 박테리오파지는 시포비리데(siphoviridae)에 속하는 박테리오파지일 수 있다. In addition, in the present invention, the bacteriophage may be a bacteriophage belonging to siphoviridae.
단, 본 발명에서 상기 “시포비리데(siphoviridae)”는 박테리오파지를 전자현미경을 통한 형태 관찰에 의해 분류 및 동정하는 방법에 의해 분류된 것으로, 수축성이 없는 수축성이 없는 긴 꼬리(a long non-contractile tail)를 갖는 복합형의 형태를 나타낸 것일 수 있다.However, in the present invention, the "siphoviridae" is classified by a method of classifying and identifying bacteriophages by morphological observation through an electron microscope, and a long non-contractile without contractility (a long non-contractile). tail) may be shown in the form of a complex type.
본 발명의 다른 구현 예에 따르면, 본 발명에 따른 박테리오파지 YMC15/11/N137_KPN_BP를 유효성분으로 포함하는 항생제 내성 클렙시엘라속 균 유발성 질환의 예방 또는 치료용 약학 조성물을 제공한다.According to another embodiment of the present invention, there is provided a pharmaceutical composition for preventing or treating an antibiotic-resistant Klebsiella genus disease-induced disease, comprising the bacteriophage YMC15/11/N137_KPN_BP according to the present invention as an active ingredient.
본 발명의 약학 조성물은 1 × 103 내지 1 × 1010 pfu/㎖의 박테리오파지를 포함하며, 바람직하게는 1 × 106 내지 1 × 109 pfu/㎖의 박테리오파지를 포함할 수 있다.The pharmaceutical composition of the present invention may include 1 × 10 3 to 1 × 10 10 pfu/ml of bacteriophage, preferably 1 × 10 6 to 1 × 10 9 pfu/ml of bacteriophage.
본 발명의 약학 조성물에 포함되는 박테리오파지 YMC15/11/N137_KPN_BP는 상술한 바와 같이, 항생제 내성 클렙시엘라속 균, 바람직하게는 카바페넴 내성 클렙시엘라속, 보다 바람직하게는 카바페넴 내성 클렙시엘라 뉴모니아를 특이적으로 사멸시킬 수 있는 용균능 및 흡착능이 존재하므로, 본 발명의 약학 조성물을 사용하는 경우 상기 항생제 내성 클렙시엘라속 균을 용균 및 사멸시켜 인체 내에서 상기 항생제 내성 클렙시엘라 속 균의 감염으로 인하여 유발되는 다양한 질환을 효과적으로 예방 또는 치료할 수 있다. As described above, the bacteriophage YMC15/11/N137_KPN_BP contained in the pharmaceutical composition of the present invention is an antibiotic-resistant Klebsiella bacterium, preferably a carbapenem-resistant Klebsiella genus, more preferably a carbapenem-resistant Klebsiella new Since there is a lytic ability and adsorption ability to specifically kill moniae, when the pharmaceutical composition of the present invention is used, the antibiotic-resistant Klebsiella genus is lysed and killed in the human body. Various diseases caused by bacterial infection can be effectively prevented or treated.
본 발명에서 상기 클렙시엘라속 균 유발성 질환은 패혈증, 폐렴 및 폐기종으로 이루어진 군에서 선택되는 어느 하나일 수 있으나, 이에 제한되는 것은 아니다. In the present invention, the Klebsiella bacteria-induced disease may be any one selected from the group consisting of sepsis, pneumonia and emphysema, but is not limited thereto.
본 명세서에서 사용된 '치료'라는 용어는 (ⅰ) 클렙시엘라속 균 에 의해 유발된 질환의 예방; (ⅱ) 클렙시엘라속 균 에 의해 유발된 질환의 억제; 및 (ⅲ) 클렙시엘라속 균 에 의해 유발된 질환의 경감을 의미한다.As used herein, the term 'treatment' refers to (i) prevention of diseases caused by bacteria of the genus Klebsiella; (ii) inhibition of diseases caused by bacteria of the genus Klebsiella; and (iii) alleviation of diseases caused by Klebsiella genus bacteria.
본 발명에서 상기 약학 조성물은 캡슐, 정제, 과립, 주사제, 연고제, 분말 또는 음료 형태임을 특징으로 할 수 있으며, 상기 약학 조성물은 인간을 대상으로 하는 것을 특징으로 할 수 있다. In the present invention, the pharmaceutical composition may be characterized in the form of capsules, tablets, granules, injections, ointments, powders or beverages, and the pharmaceutical composition may be characterized in that it is targeted to humans.
본 발명에서 상기 약학 조성물은 이들로 한정되는 것은 아니지만, 각각 통상의 방법에 따라 산제, 과립제, 캡슐, 정제, 수성 현탁액 등의 경구형 제형, 외용제, 좌제 및 멸균 주사 용액의 형태로 제형화하여 사용될 수 있다. 본 발명의 약학 조성물은 약학적으로 허용 가능한 담체를 포함할 수 있다. 약학적으로 허용되는 담체는 경구 투여 시에는 결합제, 활탁제, 붕해제, 부형제, 가용화제, 분산제, 안정화제, 현탁화제, 색소, 향료 등을 사용할 수 있으며, 주사제의 경우에는 완충제, 보존제, 무통화제, 가용화제, 등장제, 안정화제 등을 혼합하여 사용할 수 있으며, 국소투여용의 경우에는 기제, 부형제, 윤활제, 보존제 등을 사용할 수 있다. 본 발명의 약학 조성물의 제형은 상술한 바와 같은 약제학적으로 허용되는 담체와 혼합하여 다양하게 제조될 수 있다. 예를 들어, 경구 투여시에는 정제, 트로키, 캡슐, 엘릭서(elixir), 서스펜션, 시럽, 웨이퍼 등의 형태로 제조할 수 있으며, 주사제의 경우에는 단위 투약 앰플 또는 다수회 투약 형태로 제조할 수 있다. 기타, 용액, 현탁액, 정제, 캡슐, 서방형 제제 등으로 제형화할 수 있다.In the present invention, the pharmaceutical composition is not limited thereto, but each can be formulated in the form of oral dosage forms such as powders, granules, capsules, tablets, aqueous suspensions, external preparations, suppositories, and sterile injection solutions according to conventional methods. can The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers may include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments, fragrances, etc., for oral administration, and in the case of injections, buffers, preservatives, pain-freezing agents A topical agent, solubilizer, isotonic agent, stabilizer, etc. may be mixed and used, and in the case of topical administration, a base, excipient, lubricant, preservative, etc. may be used. The dosage form of the pharmaceutical composition of the present invention can be prepared in various ways by mixing with a pharmaceutically acceptable carrier as described above. For example, in the case of oral administration, it can be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and in the case of injections, it can be prepared in the form of unit dose ampoules or multiple doses. have. In addition, it can be formulated as a solution, suspension, tablet, capsule, sustained release formulation, and the like.
한편, 제제화에 적합한 담체, 부형제 및 희석제의 예로는, 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말디톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 또는 광물유 등이 사용될 수 있다. 또한, 충진제, 항 응집제, 윤활제, 습윤제, 향료, 유화제, 방부제 등을 추가로 포함할 수 있다.Meanwhile, examples of carriers, excipients and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil may be used. In addition, fillers, anti-agglomeration agents, lubricants, wetting agents, fragrances, emulsifiers, preservatives and the like may be further included.
본 발명에 상기 약학 조성물의 투여 경로는 이들로 한정되는 것은 아니지만 구강, 정맥내, 근육내, 동맥내, 골수내, 경막내, 심장내, 경피, 피하, 복강내, 비강내, 장관, 국소, 설하 또는 직장이 포함된다. 경구 또는 비경구 투하가 바람직하다.The route of administration of the pharmaceutical composition in the present invention is, but not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal. Oral or parenteral administration is preferred.
본 발명에서 상기 "비경구"란, 피하, 피내, 정맥내, 근육내, 관절내, 활액낭내, 흉골내, 경막내, 병소내 및 두개골내 주사 또는 주입기술을 포함한다. 본 발명의 약학 조성물은 또한 직장 투여를 위한 좌제의 형태로 투여될 수 있다.In the present invention, the term "parenteral" includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or injection techniques. The pharmaceutical composition of the present invention may also be administered in the form of a suppository for rectal administration.
본 발명의 상기 약학 조성물은 사용된 특정 화합물의 활성, 연령, 체중, 일반적인 건강, 성별, 정식, 투여 시간, 투여 경로, 배출율, 약물 배합 및 예방 또는 치료될 특정 질환의 중증을 포함한 여러 요인에 따라 다양하게 변할 수 있고, 상기 약학 조성물의 투여량은 환자의 상태, 체중, 질병의 정도, 약물 형태, 투여 경로 및 기간에 따라 다르지만 당업자에 의해 적절하게 선택될 수 있고, 1일 0.0001 내지 50mg/kg 또는 0.001 내지 50mg/kg으로 투여할 수 있다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. 본 발명에 따른 의약 조성물은 환제, 당의정, 캡슐, 액제, 겔, 시럽, 슬러리, 현탁제로 제형될 수 있다. The pharmaceutical composition of the present invention depends on several factors including the activity of the specific compound used, age, weight, general health, sex, formula, administration time, administration route, excretion rate, drug formulation, and the severity of the specific disease to be prevented or treated. The dosage of the pharmaceutical composition may vary depending on the patient's condition, body weight, degree of disease, drug form, administration route and period, but may be appropriately selected by those skilled in the art, and 0.0001 to 50 mg/kg per day Or 0.001 to 50 mg/kg may be administered. Administration may be administered once a day, or may be administered in several divided doses. The above dosage does not limit the scope of the present invention in any way. The pharmaceutical composition according to the present invention may be formulated as pills, dragees, capsules, solutions, gels, syrups, slurries, and suspensions.
본 발명의 또 다른 구현 예에 따르면, 본 발명에 따른 박테리오파지 YMC15/11/N137_KPN_BP를 유효성분으로 포함하는 항생제 내성 클렙시엘라속 균 유발성 질환의 예방 또는 개선용 식품 조성물을 제공한다.According to another embodiment of the present invention, there is provided a food composition for preventing or improving antibiotic-resistant Klebsiella spp. induced diseases comprising the bacteriophage YMC15/11/N137_KPN_BP according to the present invention as an active ingredient.
본 발명의 식품 조성물은 1 × 103 내지 1 × 1010 pfu/㎖의 박테리오파지를 포함하며, 바람직하게는 1 × 106 내지 1 × 109 pfu/㎖의 박테리오파지를 포함할 수 있다.The food composition of the present invention may include 1 × 10 3 to 1 × 10 10 pfu/ml of bacteriophage, preferably 1 × 10 6 to 1 × 10 9 pfu/ml of bacteriophage.
본 발명의 식품 조성물에 포함되는 박테리오파지 YMC15/11/N137_KPN_BP는 상술한 바와 같이, 항생제 내성 클렙시엘라속 균, 바람직하게는 카바페넴 내성 클렙시엘라속, 보다 바람직하게는 카바페넴 내성 클렙시엘라 뉴모니아를 특이적으로 사멸시킬 수 있는 용균능 및 흡착능이 존재하므로, 본 발명의 약학 조성물을 사용하는 경우 상기 항생제 내성 클렙시엘라속 균을 용균 및 사멸시켜 인체 내에서 상기 항생제 내성 클렙시엘라 속 균의 감염으로 인하여 유발되는 다양한 질환을 효과적으로 예방 또는 개선할 수 있다.As described above, the bacteriophage YMC15/11/N137_KPN_BP included in the food composition of the present invention is an antibiotic-resistant Klebsiella bacterium, preferably a carbapenem-resistant Klebsiella genus, more preferably a carbapenem-resistant Klebsiella new Since there is a lytic ability and adsorption ability to specifically kill moniae, when the pharmaceutical composition of the present invention is used, the antibiotic-resistant Klebsiella genus is lysed and killed in the human body. Various diseases caused by bacterial infection can be effectively prevented or improved.
본 발명에서 상기 클렙시엘라속 균 유발성 질환은 패혈증, 폐렴 및 폐기종으로 이루어진 군에서 선택되는 어느 하나인 것일 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the Klebsiella bacteria-induced disease may be any one selected from the group consisting of sepsis, pneumonia and emphysema, but is not limited thereto.
한편, 본 발명에서, “개선”은 본 발명의 식품 조성물을 이용하여 클렙시엘라속 균의 감염으로 인해 발생한 증상이 호전 또는 이롭게 변경되는 모든 행위라면 제한없이 포함할 수 있다.On the other hand, in the present invention, "improvement" may include without limitation any action in which symptoms caused by infection of the genus Klebsiella using the food composition of the present invention are improved or beneficially changed.
본 발명의 상기 박테리오파지를 유효성분으로 포함하는 식품 조성물은 각종 식품류, 예를 들어, 음료, 껌, 차, 비타민 복합제, 분말, 과립, 정제, 캡슐, 과자, 떡, 빵 등의 형태로 제조될 수 있다.The food composition comprising the bacteriophage of the present invention as an active ingredient can be prepared in the form of various foods, for example, drinks, gums, tea, vitamin complexes, powders, granules, tablets, capsules, sweets, rice cakes, breads, etc. have.
본 발명에서 상기 박테리오파지가 식품 조성물에 포함될 때 그 양은 전체 중량의 0.1 내지 50%의 비율로 첨가할 수 있으나, 이에 제한되는 것은 아니다.When the bacteriophage is included in the food composition in the present invention, the amount may be added in a proportion of 0.1 to 50% of the total weight, but is not limited thereto.
본 발명에서 상기 식품 조성물이 음료 형태로 제조되는 경우 지시된 비율로 상기 식품 조성물을 포함하는 것 외에 특별한 제한점은 없으며, 통상의 음료와 같이 다양한 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 구체적으로, 천연 탄수화물로서 포도당 등의 모노사카라이드, 과당 등의 디사카라이드, 슈크로스 등의 및 폴리사카라이드, 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜 등을 포함할 수 있다. 상기 향미제로서는 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등) 등일 수 있다.In the present invention, when the food composition is prepared in the form of a beverage, there is no particular limitation other than including the food composition in the indicated ratio, and it may contain various flavoring agents or natural carbohydrates as additional ingredients, like a conventional beverage. . Specifically, as natural carbohydrates, monosaccharides such as glucose, disaccharides such as fructose, and polysaccharides such as sucrose, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol are used as natural carbohydrates. may include The flavoring agent may be a natural flavoring agent (taumartin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agent (saccharin, aspartame, etc.).
본 발명에서, 그 외 본 발명의 상기 식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 포함할 수 있다.In the present invention, the food composition of the present invention in addition to various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and flavoring agents such as natural flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids , protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
본 발명에서 상기 성분은 독립적 또는 조합하여 사용할 수 있다. 상기 첨가제의 비율은 본 발명의 핵심적인 요소에 해당하지 아니하지만, 본 발명의 식품 조성물 100 중량부 당 0.1 내지 약 50 중량부의 범위에서 선택될 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the components may be used independently or in combination. The proportion of the additive is not a key element of the present invention, but may be selected from 0.1 to about 50 parts by weight per 100 parts by weight of the food composition of the present invention, but is not limited thereto.
본 발명의 또 다른 구현 예는 본 발명에 따른 박테리오파지 YMC15/11/N137_KPN_BP를 유효성분으로 포함하는 항생제를 제공한다.Another embodiment of the present invention provides an antibiotic comprising the bacteriophage YMC15/11/N137_KPN_BP according to the present invention as an active ingredient.
본 발명에서 상기 항생제는, 대부분의 다른 항생 물질들은 대상체인 균주의 내성이 증가함에 따라 갈수록 사용범위가 줄어들 수 밖에 없는데에 반하여, 본 발명의 상기 항생제는 상기와 같은 문제점과 무관하게 사용될 수 있으므로 항생제로 사용될 수 있는 수명이 길어질 수 있다.In the present invention, the antibiotic, most of the other antibiotics, as the resistance of the subject strain increases, the range of use is inevitably reduced, whereas the antibiotic of the present invention can be used irrespective of the above problems. The usable lifespan can be extended.
단, 본 발명에서 상기 "항생제"는 방부제, 살균제 및 항균제를 총칭하는 의미를 나타낸다.However, in the present invention, the term "antibiotic" refers to a generic term for preservatives, bactericides and antibacterial agents.
본 발명의 또 다른 구현 예는 본 발명에 따른 박테리오파지 YMC15/11/N137_KPN_BP를 유효성분으로 포함하는 소독제를 제공한다.Another embodiment of the present invention provides a disinfectant comprising the bacteriophage YMC15/11/N137_KPN_BP according to the present invention as an active ingredient.
본 발명에서 상기 소독제는 항생제 내성 클렙시엘라속 균에 대하여 특이적 사멸능을 갖는 박테리오파지를 유효성분으로 하고 있으므로, 병원에서의 감염을 방지하기 위한 병원 및 보건용 도구 등의 소독제로 유용하게 사용될 수 있고, 일반 생활 소독제, 식품 및 조리 장소 및 설비의 소독제, 축산 산업의 축사 소독제로 유용하게 사용될 수 있다.In the present invention, the disinfectant is a bacteriophage having a specific killing ability against an antibiotic-resistant Klebsiella genus as an active ingredient, so it can be usefully used as a disinfectant for hospitals and health tools to prevent infection in hospitals. It can be usefully used as a disinfectant for general living, a disinfectant for food and cooking places and equipment, and a disinfectant for livestock in the livestock industry.
본 발명에 따른 신규한 박테리오파지는 항생제 내성 클렙시엘라속 균에 대하여 특이적 사멸능을 가지므로, 항생제 내성 클렙시엘라속 균에 의해 유발되는 질환의 예방 및 치료 목적으로 활용할 수 있다.Since the novel bacteriophage according to the present invention has a specific killing ability against antibiotic-resistant bacteria of the genus Klebsiella, it can be used for prevention and treatment of diseases caused by bacteria of the genus antibiotic-resistant.
도 1은 본 발명의 일 실시예에 따른 박테리오파지의 전자 현미경 촬영 사진을 나타낸 것이다.
도 2는 본 발명의 일 실시예에 따른 항생제 내성을 갖는 클렙시엘라속 균에 대한 용균성 박테리오파지의 흡창능을 그래프로 나타낸 것이다.
도 3은 본 발명의 일 실시예에 따른 항생제 내성을 갖는 클렙시엘라속 균에 대한 용균성 박테리오파지의 1단 증식 곡선을 나타낸 것이다.
도 4는 본 발명의 일 실시예에 따른 생체 외에서 박테리오파지의 항생제 내성을 갖는 클렙시엘라속 균에 대한 용균능을 그래프로 나타낸 것이다.
도 5는 본 발명의 일 실시예에 따른 항생제 내성을 갖는 클렙시엘라속 균에 대한 용균성 박테리오파지의 pH 안정성을 그래프로 나타낸 것이다.
도 6은 본 발명의 일 실시예에 따른 항생제 내성을 갖는 클렙시엘라속 균에 대한 용균성 박테리오파지의 온도 안정성을 그래프로 나타낸 것이다.
도 7은 본 발명의 일 실시예에 따른 항생제 내성을 갖는 클렙시엘라속 균에 대한 용균성 박테리오파지의 전체 유전체 서열 분석 결과를 나타낸 것이다.1 shows an electron microscope photograph of a bacteriophage according to an embodiment of the present invention.
Figure 2 is a graph showing the absorption capacity of the lytic bacteriophage for Klebsiella genus bacteria having antibiotic resistance according to an embodiment of the present invention.
Figure 3 shows the one-stage proliferation curve of the lytic bacteriophage for the genus Klebsiella having antibiotic resistance according to an embodiment of the present invention.
Figure 4 is a graph showing the lytic ability of the bacteriophage in vitro bacteriophage antibiotic resistance against the genus Klebsiella according to an embodiment of the present invention.
Figure 5 is a graph showing the pH stability of the lytic bacteriophage for the bacteria of the genus Klebsiella having antibiotic resistance according to an embodiment of the present invention.
Figure 6 is a graph showing the temperature stability of the lytic bacteriophage for the genus Klebsiella having antibiotic resistance according to an embodiment of the present invention.
Figure 7 shows the whole genome sequence analysis result of the lytic bacteriophage for the genus Klebsiella having antibiotic resistance according to an embodiment of the present invention.
이하, 본 발명을 하기의 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by the following examples. However, the following examples are only illustrative of the present invention, and the content of the present invention is not limited by the following examples.
실시예Example
[[ 실시예Example 1] 임상검체 분리 및 항생제 내성 균주 선별 1] Isolation of clinical specimens and selection of antibiotic-resistant strains
세브란스 병원 환자들로부터 환자의 분변 내 클렙시엘라 뉴모니아(Klebsiella pneumoniae) 균을 배양하여 분리하였다. 그 뒤, 감수성 결과는 Clinical and Laboratory Standards Institute (CLSI, 2009)를 기준으로 판독하였다. 감수성 시험은 뮬러-힌튼(Mueller-Hinton) 아가를 사용하여 외기 37℃에서 하룻밤 동안 배양하는 CLSI 디스크 확산 시험방법을 사용하였다. 클렙시엘라 뉴모니아 균에 대한 시험 항생제는 아미카신(Amicacin), 앰피실린(Ampicillin), 엠피실린/설벡탐(Ampicillin/Sulbactam), 아즈트레오남(Aztreonam), 세즈타지딤(Ceftazidime), 세파졸린(Cefazolin), 에르타페넴(Ertapenem), 세페핌(Cefepime), 세폭시틴(Cefoxitin), 세포탁심(Cefotaxime), 젠타마이신(Gentamicine), 레보플록사신(Levofloxacin), 메로페넴(Meropenem), 피페라실린/타조박탐(Piperacillin/Tazobactam), 코트리목사(Cotrimoxa), 및 티게틸린(Tigecyline)을 사용하였다. 수집된 클렙시엘라 뉴모니아(Klebsiella pneumoniae) 53개 주의 항생제 내성 프로파일은 하기 표 1에 나타내었다. 단, 하기 표 1에서 S, I 및 R은 항균제에 대한 감수성을 평가한 결과로, 'S'는 민감(Susceptible), 'I'는 중간(Intermediate), 'R'은 내성(Resistant)를 의미한다. Klebsiella pneumoniae in the feces of patients from Severance Hospital patients was cultured and isolated. Thereafter, the sensitivity results were read based on the Clinical and Laboratory Standards Institute (CLSI, 2009). Sensitivity test was performed using a Mueller-Hinton agar, using the CLSI disk diffusion test method incubated overnight at 37 ° C. outside air. Test antibiotics for Klebsiella pneumoniae are Amikacin, Ampicillin, Ampicillin/Sulbactam, Aztreonam, Ceftazidime, Cefazolin, Ertapenem, Cefepime, Cefoxitin, Cefotaxime, Gentamicine, Levofloxacin, Meropenem, Ppi Peracillin/Tazobactam (Piperacillin/Tazobactam), Cotrimoxa, and Tigecyline were used. Collected Klebsiella pneumoniae pneumoniae ) Antibiotic resistance profiles of 53 strains are shown in Table 1 below. However, in Table 1 below, S, I and R are the results of evaluating the sensitivity to antibacterial agents, 'S' means sensitive (Susceptible), 'I' means intermediate, and 'R' means resistance. do.
상기 표 1에서 보는 바와 같이, 수집된 클렙시엘라 뉴모니아(Klebsiella pneumoniae) 53개 균주는 다양한 카바페넴계 항생제에 대하여 내성을 가지며, 특히 클렙시엘라 뉴모니아 YMC15/11/N137는 이후 PCR을 수행한 결과 bla KPC 유전자를 갖는 다재내성 균주임을 알 수 있었다.As shown in Table 1, the collected Klebsiella pneumoniae 53 strains have resistance to various carbapenem-based antibiotics, and in particular, Klebsiella pneumoniae YMC15/11/N137 is PCR As a result of performing the bla KPC gene was found to be a multi-resistant strain.
[[ 실시예Example 2] 박테리오파지 검체 수집 2] Bacteriophage sample collection
2-1. 파지 은행 구축을 위한 검체 수집2-1. Specimens collection to build phage banks
세브란스 병원의 하수 처리시설에서 최초 침전지 거친 후 부유물질 및 침사물이 제거된 원수를 확보하였다. 이는 화학 처리 시설 전 단계의 하수로 제한하였다. 수집한 시료에 1L 당 염화나트륨 58g을 첨가한 후 10,000g에서 10분간 원심 분리하여 220nm 밀리포어 필터로 여과하였다. 얻어진 여과액에 폴리에틸렌글리콜(PEG, 분자량 8000)을 10% W/V으로 첨가하고 4에서 12시간 동안 냉장 보관하였다. 12시간 냉장 보관된 여과액을 12,000g에서 20분간 원심 분리하여 침전물을 파지 희석 완충액 (SM 완충액)에 재부유한 뒤, 동일한 양의 클로로포름을 첨가하여 냉동 보관하였다. 이를 3회 반복하여 300mL의 박테리오파지 부유액을 채취하였다.After going through the first sedimentation pond at Severance Hospital's sewage treatment facility, raw water from which suspended matter and sediment were removed was obtained. This was limited to sewage from the pre-chemical treatment plant. After adding 58 g of sodium chloride per 1 L to the collected sample, centrifugation was performed at 10,000 g for 10 minutes, followed by filtration through a 220 nm Millipore filter. Polyethylene glycol (PEG, molecular weight 8000) was added to the obtained filtrate at 10% W/V, and the mixture was refrigerated for 4 to 12 hours. The filtrate stored in refrigeration for 12 hours was centrifuged at 12,000 g for 20 minutes to resuspend the precipitate in phage dilution buffer (SM buffer), and then the same amount of chloroform was added and stored frozen. This was repeated three times to collect 300 mL of bacteriophage suspension.
2-2 2-2 용균성lytic 파지 선별 및 phage screening and 용균역가lysis titer 측정 Measure
용균성 파지의 분리 정제는 스팟 테스트(Spot Test)법 (Mazzocco A et al. In Bacteriophages, Clokie and Kropinski AM, eds. Humana Press. 2009)으로 실행하였다. 확보된 균주를 맥콘키 한천배지에서 접종 후 외기 35에서 하룻밤 동안 배양하였다. 배양 후, 투명한 플라크 형성을 보고 파지에 감수성인 균주를 선별하였다. 감수성인 균주를 맥콘키 한천 배지에 접종하여 35에서 12시간 동안 배양하였다. 살린 1ml 튜브에 McFarland 0.5 탁도로 각 균주의 현탁액 제조하고 H 탑 아가 (3 ml), 감수성 박테리아 100ul 및 파지 용액 (각각 1ul, 10ul 및 50ul)을 섞어 LB 아가에 도포한 후, 35에서 12시간 동안 배양하였다. 플라크 관찰한 후에 파스퇴르 파이펫으로 플라크를 채취하여 SM 완충 용액에 희석하고, 다시 감수성인 균주 현탁액을 이용하여 3회 반복 정제하였다. 이렇게 얻어진 순수한 박테리오파지는 SM 완충 용액에 희석하고 다시 감수성인 균주 현탁액을 이용하여 3회 반복 정제하였다. 이렇게 얻어진 순수한 박테리오파지는 SM 완충 용액에 희석하여 보관하였다.Separation and purification of lytic phage was performed by the Spot Test method (Mazzocco A et al. In Bacteriophages, Clokie and Kropinski AM, eds. Humana Press. 2009). The obtained strain was inoculated on McConkie agar medium and then cultured overnight at 35 outside air. After incubation, strains susceptible to phage were selected by looking at the formation of transparent plaques. Sensitive strains were inoculated on McConkey agar medium and cultured for 12 hours at 35°C. A suspension of each strain was prepared in a saline 1ml tube with McFarland 0.5 turbidity, mixed with H top agar (3 ml), 100ul of susceptible bacteria and phage solution (1ul, 10ul and 50ul, respectively) and applied to LB agar, and then applied to LB agar for 35 to 12 hours. cultured. After observing the plaque, the plaque was collected with a Pasteur pipette, diluted in SM buffer solution, and purified three times using a suspension of the susceptible strain again. The pure bacteriophage thus obtained was diluted in SM buffer solution and purified three times using a suspension of a susceptible strain again. The pure bacteriophage thus obtained was diluted and stored in SM buffer solution.
실시예 1에서 확인한 항생제 내성 클렙시엘라 뉴모니아(Klebsiella pneumoniae) 53개 균주 각각을 맥콘키 한천배지에서 접종하여 배양한 후, 상기 과정에 의해 정제된 박테리오파지 YMC15/11/N137_KPN_BP를 도말된 각각의 내성 균주에 5ul로 접종하여 플라그 형성을 확인하고, 역가 범위를 확인하여, 용균성을 하기 표 2에 나타내었다. Antibiotic-resistant Klebsiella pneumoniae confirmed in Example 1 After inoculating and culturing each of 53 strains on McConkie agar medium, the bacteriophage YMC15/11/N137_KPN_BP purified by the above process was plated on each By inoculating the resistant strain with 5ul, the formation of plaque was confirmed, the titer range was confirmed, and the lytic properties are shown in Table 2 below.
단, 상기 표 2에서 + 및 -는 수집된 균주에 대한 플라크 활성을 평가한 것으로, '+'는 투명한 플라크(clear plaque)를 의미하고, '-'는 용균이 일어나지 않은 것을 의미한다.However, in Table 2, + and - indicate the evaluation of plaque activity against the collected strain, '+' means clear plaque, and '-' means no lysis.
상기 표 2에서 보는 바와 같이, 본 발명에 따른 박테리오파지 YMC15/11/N137_KPN_BP는 항생제 내성 클렙시엘라 뉴모니아 53개 균주 중 46개 균주(87%)를 용균 시키는 것을 확인할 수 있었다.As shown in Table 2, the bacteriophage YMC15/11/N137_KPN_BP according to the present invention was confirmed to lyse 46 strains (87%) of 53 strains of antibiotic-resistant Klebsiella pneumoniae.
[[ 실시예Example 3] 항생제 내성 3] Antibiotic resistance 클렙시엘라Klebsiella 뉴모니아균에in pneumonia 대한 About 용균성lytic 박테리오파지의 전자 현미경 분석 Electron Microscopy Analysis of Bacteriophages
상기 실시예 2의 방법에 의해 정제된 박테리오파지를 감수성 균주 배양 배지(20ml LB 배지)에 접종 및 배양한 뒤 220nm 밀리포어 필터로 여과하고, 상청액에 폴리에틸렌글리콜(MW 8,000)을 10%(w/v)의 양으로 첨가한 후 밤새 냉장 보관하였다. 이후 12,000g의 조건으로 20분 동안 원심 분리한 뒤, 에너지 여과 투과 전자현미경(Energy-Filtering Transmission Electron Microscope)을 이용하여 박테리오파지의 형태를 분석하여, 그 결과를 도 1에 나타내었다.The bacteriophage purified by the method of Example 2 was inoculated and cultured in a sensitive strain culture medium (20ml LB medium) and then filtered through a 220nm Millipore filter, and polyethylene glycol (MW 8,000) in the supernatant was 10% (w / v) ) and then refrigerated overnight. After centrifugation for 20 minutes under the conditions of 12,000 g, and then using an energy-filtering transmission electron microscope (Energy-Filtering Transmission Electron Microscope) to analyze the shape of the bacteriophage, the results are shown in FIG.
도 1에서 보는 바와 같이, 본 발명에 따른 상기 YMC15/11/N137_KPN_BP 박테리오파지를 모양으로 분류하는 기준으로 보았을 때, 파지가 수축성이 없는 긴 꼬리(a long non-contractile tail)를 갖고, 시스(sheath)가 없으므로 시포비리대(Siphoviridae)에 속하는 것으로 분류하였다.As shown in FIG. 1, when viewed as a criterion for classifying the YMC15/11/N137_KPN_BP bacteriophage according to the present invention by shape, the phage has a long non-contractile tail without contractility, and a sheath It was classified as belonging to Siphoviridae.
[[ 실시예Example 4] 4] 박페리오파지의Bacteriophage 흡착능adsorption capacity 및 1단 증식 곡선(One-step growth curve) 분석 and One-step growth curve analysis
항생제 내성을 갖는 클렙시엘라 뉴모니아균을 OD 값이 0.5가 되도록 배양한 뒤, 클렙시엘라 뉴모니아균에 상기 실시예 2에서 정제된 박테리오파지 YMC15/11/N137_KPN_BP를 MOI 0.001로 넣고 상온에서 배양한 뒤, 100ul 시료를 1, 2, 3, 4, 5분에 1ml씩 채취하여 LB 배지에 희석한 뒤 플라그 분석을 통해 상기 박테리오파지의 흡착능을 평가하여, 그 결과를 도 2에 나타내었다.After culturing Klebsiella pneumoniae having an antibiotic resistance to an OD value of 0.5, the bacteriophage YMC15/11/N137_KPN_BP purified in Example 2 was added to Klebsiella pneumoniae at an MOI of 0.001 and cultured at room temperature. Then, 100ul samples were collected by 1ml every 1, 2, 3, 4, 5 minutes, diluted in LB medium, and then the adsorption capacity of the bacteriophage was evaluated through plaque analysis, and the results are shown in FIG. 2 .
또한, 항생제 내성을 갖는 클렙시엘라 뉴모니아균을 OD 값이 0.3이 되도록 배양한 뒤, 4에서 5분 동안 7,000g로 원심 분리하여 세포를 침전시킨 후, 0.5ml의 LB 배지에 희석시키고, 상기 실시예 2에서 정제된 박테리오파지를 MOI 0.001(titer 108pfu/cells)를 넣고 37에서 5분 동안 배양하였다. 배양된 혼합 시료를 13,000g에서 1분 동안 원심 분리하여 얻어진 펠렛을 10ml의 LB 배지에 희석시키고 37에서 배양하였다. 배양 도중 10분 마다 시료를 채취하여 플라그 분석을 통해 상기 박테리오파지의 1단 증식 곡선을 평가하여, 그 결과를 도 3에 나타내었다.In addition, after culturing Klebsiella pneumoniae having an antibiotic resistance to an OD value of 0.3, centrifugation at 7,000 g for 4 to 5 minutes to precipitate the cells, diluted in 0.5 ml of LB medium, and The bacteriophage purified in Example 2 was put into MOI 0.001 (
도 2에서 보는 바와 같이, 상기 YMC15/11/N137_KPN_BP 박테리오파지의 접종 후 5분 이내에 박테리오파지의 94% 정도가 클렙시엘라 뉴모니아균에 흡착하였다.As shown in Figure 2, within 5 minutes after inoculation of the YMC15/11/N137_KPN_BP bacteriophage, about 94% of the bacteriophage was adsorbed to Klebsiella pneumoniae.
또한, 도 3에서 보는 바와 같이, 1단 증식 곡선 결과 17PFU/감염 세포의 높은 버스트 사이즈를 나타내었다.In addition, as shown in FIG. 3, the result of the single-stage proliferation curve showed a high burst size of 17 PFU/infected cells.
상기 결과를 통해 본 발명에 따른 상기 YMC15/11/N137_KPN_BP 박테리오파지는 항생제 내성을 갖는 클렙시엘라 뉴모니아균에 비교적 빠른 시간 내에 흡착할 수 있고, 17 PFU/감염 세포의 높은 버스트 사이즈를 나타내 항생제 내성 균주의 용균 효과를 발휘하는 것을 알 수 있다.Through the above results, the YMC15/11/N137_KPN_BP bacteriophage according to the present invention can adsorb in a relatively fast time to Klebsiella pneumoniae having antibiotic resistance, and 17 PFU/infected cells exhibit a high burst size of antibiotic-resistant strains. It can be seen that the lytic effect of
[[ 실시예Example 5] 생체 외 항생제 내성 5] In vitro antibiotic resistance 클렙시엘라Klebsiella 속 균에 대한 박테리오파지의 용균능 검증 Verification of the lytic ability of bacteriophages against genus bacteria
항생제 내성 클렙시엘라 뉴모니아균 1 X 109 CFU/ml에 준비된 박테리오파지 YMC15/11/N137_KPN_BP를 1 X 108 CFU/ml(MOI: 0.1), 1 X 109 PFU/ml(MOI: 1), 1 X 1010 PFU/ml(MOI: 10)의 양으로 각각 처리하고 시간 별로 OD 값(파장 600nm)을 측정하였다. 단, 음성 대조군으로는 PBS+SM 버퍼를 처리하여, 그 값을 도 4에 나타내었다.Antibiotic-resistant Klebsiella pneumoniae 1
도 4에서 보는 바와 같이, 음성 대조군과 비교할 때, 클렙시엘라 뉴모니아균에 대하여 박테리오파지를 처리한 경우 OD 값이 감소하였고, MOI 값이 증가할수록 OD 값은 더욱 감소하였다.As shown in FIG. 4 , when compared to the negative control group, when the bacteriophage was treated for Klebsiella pneumoniae, the OD value was decreased, and as the MOI value increased, the OD value was further decreased.
상기 결과를 통해, 본 발명에 따른 박테리오파지는 항생제 내성 클렙시엘라 뉴모니아균에 대하여 용균성을 갖는 것을 알 수 있다.Through the above results, it can be seen that the bacteriophage according to the present invention has lytic properties against antibiotic-resistant Klebsiella pneumoniae.
[[ 실시예Example 6] 항생제 내성 6] Antibiotic resistance 클렙시엘라Klebsiella 속 균에 대한 박테리오파지의 안정성 평가 Stability evaluation of bacteriophages against genus bacteria
본 발명에 따른 YMC15/11/N137_KPN_BP 박테리오파지가 온도 및 알칼리에서 파괴되지 않고 안정성을 유지하는지 확인하였다.It was confirmed whether the YMC15/11/N137_KPN_BP bacteriophage according to the present invention maintains stability without being destroyed in temperature and alkali.
상기 실시예 2의 방법에 의해 정제된 박테리오 파지 1 ㎕를 4, 5, 6, 7, 8, 9 및 10의 pH로 맞춘 SM 버퍼 40 ㎕에 넣은 뒤, 37℃에서 1시간 동안 배양한 뒤 항생제 내성 클렙시엘라 뉴모니아균과 함께 상기 실시예 4의 방법으로 플라크 분석을 실시하여 그 결과를 도 5에 나타내었다.1 μl of the bacteriophage purified by the method of Example 2 was placed in 40 μl of SM buffer adjusted to a pH of 4, 5, 6, 7, 8, 9 and 10, followed by incubation at 37° C. for 1 hour and then antibiotics Plaque analysis was performed by the method of Example 4 together with resistant Klebsiella pneumoniae, and the results are shown in FIG. 5 .
또한, 상기 박테리오파지 용액을 각각 40℃, 50℃, 60℃ 및 70℃에서 배양하는 1시간 동안 10분 단위로 각각의 샘플을 클렙시엘라 뉴모니아균과 함께 상기 실시예 4의 방법으로 플라크 분석을 실시하여 그 결과를 도 6에 나타내었다.In addition, the bacteriophage solution is incubated at 40 ° C., 50 ° C., 60 ° C. and 70 ° C. for 1 hour, each sample with Klebsiella pneumoniae. Plaque analysis by the method of Example 4 and the results are shown in FIG. 6 .
도 5에서 보는 바와 같이, 본 발명에 따른 상기 파지는 pH 7에 해당하는 중성에서 가장 안정성을 나타내었고, 14일 동안 산성에 비해서는 알칼리성에서 비교적 안정성을 나타내었다.As shown in FIG. 5 , the phage according to the present invention exhibited the most stability at a neutral pH corresponding to a pH of 7, and exhibited relatively stability in alkali compared to acid for 14 days.
또한, 도 6에서 보는 바와 같이, 상기 파지는 60℃에서 20분까지 30% 이상의 활성을 보일 정도로 높은 안정성을 보였다. In addition, as shown in FIG. 6 , the phage showed high stability enough to show 30% or more activity at 60° C. for 20 minutes.
[[ 실시예Example 7] 항생제 내성 7] Antibiotic resistance 클렙시엘라Klebsiella 속 균에 대한 박테리오파지의 전체 게놈 서열 분석 Whole genome sequence analysis of bacteriophages for genus bacteria
본 발명에 따른 상기 YMC15/11/N137_KPN_BP 박테리오파지의 특성을 규명하기 위하여 전체 유전자 서열 분석을 Illumina sequencer(Roche)를 통하여 통상의 기술자에게 자명한 전체 게놈 서열 분석 방법을 기초로 분석하여, 그 결과를 도 7 및 표 3에 나타내었다.In order to characterize the YMC15/11/N137_KPN_BP bacteriophage according to the present invention, the whole genome sequence analysis is performed based on the whole genome sequence analysis method that is obvious to those skilled in the art through the Illumina sequencer (Roche), and the results are shown. 7 and Table 3.
(strand)strand
(strand)
(bp)Length
(bp)
(Putative function)Estimation function
(Putative function)
(Annotation source)Annotation Source
(Annotation source)
identity (%)NCBI blastP
identity (%)
도 7 및 상기 표 3에서 보는 바와 같이, 본 발명에 따른 YMC15/11/N137_KPN_BP 박테리오파지가 용균 효과를 나타내는 단백질을 코딩하는 유전자의 서열은 ORF48(holing), ORF49 및 ORF73(endolysin) 등에 해당하였다.As shown in Figure 7 and Table 3, the sequence of the gene encoding the protein showing the lytic effect of the YMC15/11/N137_KPN_BP bacteriophage according to the present invention corresponds to ORF48 (holing), ORF49 and ORF73 (endolysin) and the like.
삭제delete
본 발명에 따른 YMC15/11/N137_KPN_BP 박테리오파지의 서열을 기존의 박테리오파지의 서열과 대조한 결과, 본 발명에 따른 박테리오파지와 유사성을 갖는 박테리오파지는 검출되지 않았다.As a result of comparing the sequence of the YMC15/11/N137_KPN_BP bacteriophage according to the present invention with the sequence of the existing bacteriophage, the bacteriophage having similarity to the bacteriophage according to the present invention was not detected.
상기 결과를 통해 본 발명에 따른 YMC15/11/N137_KPN_BP 박테리오파지는 기존에 발견되지 않은 신규한 박테리오파지에 해당함을 알 수 있다.Through the above results, it can be seen that the YMC15/11/N137_KPN_BP bacteriophage according to the present invention corresponds to a novel bacteriophage that has not been previously discovered.
이상에서 본 발명에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고, 청구범위에 기재된 본 발명의 기술적 사상을 벗어나지 않는 범위 내에서 다양한 수정 및 변형이 가능하다는 것은 당 기술분야의 통상의 지식을 가진 자에게는 자명할 것이다.Although the present invention has been described in detail above, the scope of the present invention is not limited thereto, and it is common in the art that various modifications and variations are possible without departing from the technical spirit of the present invention described in the claims. It will be self-evident to those who have the knowledge of
Claims (15)
상기 카바페넴은 앰피실린(Ampicillin), 엠피실린/설벡탐(Ampicillin/Sulbactam), 아즈트레오남(Aztreonam), 세즈타지딤(Ceftazidime), 세파졸린(Cefazolin), 에르타페넴(Ertapenem), 세페핌(Cefepime), 세폭시틴(Cefoxitin), 세포탁심(Cefotaxime), 젠타마이신(Gentamicine), 레보플록세신(Levoflocacin), 메로페넴(Meropenem), 피페라실린/타조박탐(Piperacillin/Tazobactam), 코트리목사(Cotrimoxa), 및 티게틸린(Tigecyline)으로 구성된 군으로부터 선택되는 1종 이상인, 박테리오파지.Carbapenem (Carbapenem) resistant Klebsiella pneumoniae has a specific cell killing ability, the name is YMC15/11/N137_KPN_BP, the accession number is [KCTC18573P], as a bacteriophage,
The carbapenem is ampicillin, ampicillin/sulbactam, aztreonam, ceftazidime, cefazolin, ertapenem, cefepime (Cefepime), Cefoxitin, Cefotaxime, Gentamicine, Levoflocacin, Meropenem, Piperacillin/Tazobactam, Cotri Pastor (Cotrimoxa), and Tigetyline (Tigecyline) at least one selected from the group consisting of, bacteriophage.
상기 박테리오파지는 시포비리데(Siphoviridae)에 속하는, 박테리오파지.The method of claim 1,
The bacteriophage belongs to the Siphoviridae (Siphoviridae), bacteriophage.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170077539A KR102264514B1 (en) | 2017-06-19 | 2017-06-19 | Lytic bacteriophage specific for klebsiella genus resistant to antibiotics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170077539A KR102264514B1 (en) | 2017-06-19 | 2017-06-19 | Lytic bacteriophage specific for klebsiella genus resistant to antibiotics |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180137814A KR20180137814A (en) | 2018-12-28 |
KR102264514B1 true KR102264514B1 (en) | 2021-06-18 |
Family
ID=65008531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170077539A KR102264514B1 (en) | 2017-06-19 | 2017-06-19 | Lytic bacteriophage specific for klebsiella genus resistant to antibiotics |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102264514B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020231609A1 (en) * | 2019-03-07 | 2021-10-28 | Biomx Ltd. | Bacteriophage for modulating inflammatory bowel disease |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015523850A (en) | 2012-05-04 | 2015-08-20 | バイオコントロール リミテッドBiocontrol Limited | Therapeutic bacteriophage composition |
WO2017081709A1 (en) | 2015-11-09 | 2017-05-18 | Universita' Degli Studi Di Siena | Bacteriophage able to lyse klebsiella pneumoniae expressing a cpskkbo-4 capsular polysaccharide and related medical uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1487273B1 (en) * | 2002-02-13 | 2009-01-21 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
-
2017
- 2017-06-19 KR KR1020170077539A patent/KR102264514B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015523850A (en) | 2012-05-04 | 2015-08-20 | バイオコントロール リミテッドBiocontrol Limited | Therapeutic bacteriophage composition |
WO2017081709A1 (en) | 2015-11-09 | 2017-05-18 | Universita' Degli Studi Di Siena | Bacteriophage able to lyse klebsiella pneumoniae expressing a cpskkbo-4 capsular polysaccharide and related medical uses thereof |
Non-Patent Citations (1)
Title |
---|
Current Microbiology. volume 59, pages 274-281(2009). |
Also Published As
Publication number | Publication date |
---|---|
KR20180137814A (en) | 2018-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10568917B2 (en) | Pasteurella multocida bacteriophage Pas-MUP-1 and use thereof for inhibiting proliferation of Pasteurella multocida | |
US11412760B2 (en) | Escherichia coli bacteriophage Esc-COP-7, and use thereof for suppressing proliferation of pathogenic Escherichia coli | |
US20180000125A1 (en) | Novel lactococcus garvieae bacteriophage lac-gap-1 and use thereof in suppressing proliferation of lactococcus garvieae bacteria | |
US11529406B2 (en) | Clostridium perfringens bacteriophage Clo-PEP-2 and use for inhibiting Clostridium perfringens proliferation of same | |
WO2016108542A1 (en) | Novel enteroinvasive e. coli bacteriophage esc-cop-4 and use thereof for inhibiting proliferation of enteroinvasive e. coli | |
EP3587565A1 (en) | Novel enterococcus faecium bacteriophage ent-fap-4 and use for inhibiting enterococcus faecium proliferation of same | |
US20210283202A1 (en) | E. coli bacteriophage esc-cop-14 and use thereof in inhibiting growth of pathogenic e. coli | |
US11497216B2 (en) | Pseudomonas aeruginosa bacteriophage pse-AEP-4 and use thereof for inhibiting proliferation of Pseudomonas aeruginosa | |
US11457635B2 (en) | Pseudomonas aeruginosa bacteriophage Pse-AEP-3 and use thereof for inhibiting proliferation of Pseudomonas aeruginosa | |
US20210163897A1 (en) | Novel streptococcus suis bacteriophage str-sup-2, and use thereof for inhibiting proliferation of streptococcus suis strains | |
US20210161977A1 (en) | Novel streptococcus suis bacteriophage str-sup-1 and use thereof in inhibiting streptococcus suis bacterium proliferation | |
KR102264514B1 (en) | Lytic bacteriophage specific for klebsiella genus resistant to antibiotics | |
US20210161978A1 (en) | Novel streptococcus suis bacteriophage str-sup-3, and use thereof for inhibiting proliferation of streptococcus suis strains | |
US20210085733A1 (en) | Novel aeromonas hydrophila bacteriophage aer-hyp-3 and use thereof for inhibiting growth of aeromonas hydrophila bacteria | |
KR101940019B1 (en) | Lytic bacteriophage specific for klebsiella genus resistant to antibiotics | |
US20190321423A1 (en) | Escherichia coli bacteriophage esc-cop-9 and use for inhibiting proliferation of pathogenic escherichia coli thereof | |
KR101789877B1 (en) | Lytic bacteriophage specific for Pseudomonas genus resistant to antibiotics | |
KR102011965B1 (en) | Lytic bacteriophage specific for klebsiella genus resistant to antibiotics | |
KR102011956B1 (en) | Lytic bacteriophage specific for klebsiella genus resistant to antibiotics | |
KR101788401B1 (en) | Lytic bacteriophage specific for Pseudomonas genus resistant to antibiotics | |
WO2023063453A1 (en) | Bacteriophage specific to pseudomonas having antibiotic resistance | |
Sorour et al. | Virulence Range and New Pathological Pictures of Salmonella enteridits and Salmonella typhimurium Isolated from Ducklings in Experimental Infected Chicks | |
CN114480307B (en) | Pasteurella phage vB_Pmu P_PS30, phage composition and application thereof | |
Hussein et al. | Application of salmonella phage cocktail to control salmonella typhimurium in vitro | |
US11583565B2 (en) | Compositions and methods for inhibiting the proliferation of pathogenic Escherichia coli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2020101000303; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20200129 Effective date: 20200826 |
|
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant |